{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:44:42Z","timestamp":1792799082685,"version":"4.5.0"},"reference-count":43,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2023-19-7"],"award-info":[{"award-number":["320.6750.2023-19-7"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Society of Clinical Oncology Research","award":["Y-tongshu2021\/ms-0107"],"award-info":[{"award-number":["Y-tongshu2021\/ms-0107"]}],"id":[{"id":"https:\/\/ror.org\/05sfnze82","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hubei Xiaoping Chen Science and Technology Development Foundation","award":["CXPJJH122006-1003"],"award-info":[{"award-number":["CXPJJH122006-1003"]}]},{"name":"Beijing Bethune Public Welfare Foundation","award":["BJ-GYQZHX2021006"],"award-info":[{"award-number":["BJ-GYQZHX2021006"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872429"],"award-info":[{"award-number":["81872429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Open Research Fund of Hubei Province Key Laboratory of Precision Radiation Oncology","award":["2014ZLJZFL014"],"award-info":[{"award-number":["2014ZLJZFL014"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) in combination with antiangiogenic drugs have shown promising outcomes in the third-line and subsequent treatments of patients with microsatellite stable metastatic colorectal cancer (MSS-mCRC). Radiotherapy (RT) may enhance the antitumor effect of immunotherapy. However, the effect of RT exposure on patients receiving ICIs and targeted therapy remains unclear. This study aimed to investigate the association between RT exposure and clinical responses to fruquintinib (a highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor) plus sintilimab (an anti-programmed death 1 antibody; F&amp;S) in previously treated patients with MSS-mCRC and to explore predictive biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective observational study, patients with mCRC receiving F&amp;S as third-line or subsequent treatment were enrolled. Eligible patients were divided into the RT cohort (RTC) and the non-RT cohort (NRTC) according to their RT history. The primary endpoint was the objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Pretreatment fecal and serum samples were collected for microbiome analysis, metabolome analysis, and immune signatures to identify biomarkers for treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 55 patients were included, of which 25 were in the RTC and 30 in the NRTC. Better ORR (28.0% vs 6.7%, p=0.048), DCR (80.0% vs 36.7%, p=0.002), median PFS (6.2 vs 2.7 months, p&lt;0.001), and median OS (14.8 vs 5.9 months, p=0.019) were noted in patients with RTC than those with NRTC. The enrichment of\n                      <jats:italic>Lactobacillus<\/jats:italic>\n                      ,\n                      <jats:italic>Bifidobacterium<\/jats:italic>\n                      , and PC(20:5(5Z,8Z,11Z,14Z,17Z)\/20:3(8Z,11Z,14Z)) in RTC significantly predicted better DCR and PFS, whereas guanosine and interleukin-10 predominated in patients with NRTC were negatively correlated with PFS and OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with RT exposure benefited significantly from F&amp;S in the third-line or subsequent treatment for MSS-mCRC. Gut microbiota, metabolites, and cytokines may help predict F&amp;S outcomes for mCRC, which may be helpful in treatment decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05635149\">NCT05635149<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009415","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:14:10Z","timestamp":1736147650000},"page":"e009415","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05635149","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mingxia","family":"Cheng","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Province Key Laboratory of Precision Radiation Oncology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jin","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pindong","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuying","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xue","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Hu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-3393","authenticated-orcid":false,"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-1468","authenticated-orcid":false,"given":"Hongli","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Province Key Laboratory of Precision Radiation Oncology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"2025100308264302000_13.1.e009415.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2025100308264302000_13.1.e009415.2","first-page":"165","article-title":"Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion","volume":"19","author":"Fern\u00e1ndez-Montes","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"2025100308264302000_13.1.e009415.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2025100308264302000_13.1.e009415.4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2025100308264302000_13.1.e009415.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"2025100308264302000_13.1.e009415.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025100308264302000_13.1.e009415.7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"2025100308264302000_13.1.e009415.8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100308264302000_13.1.e009415.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296"},{"key":"2025100308264302000_13.1.e009415.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3416"},{"key":"2025100308264302000_13.1.e009415.11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"The Lancet"},{"key":"2025100308264302000_13.1.e009415.12","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent updates on Sintilimab in solid tumor immunotherapy","volume":"8","author":"Liu","year":"2020","journal-title":"Biomark Res"},{"key":"2025100308264302000_13.1.e009415.13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","article-title":"Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases","volume":"181","author":"Guo","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025100308264302000_13.1.e009415.14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.semcancer.2022.04.003","article-title":"Radiation therapy-induced remodeling of the tumor immune microenvironment","volume":"86","author":"Charpentier","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2025100308264302000_13.1.e009415.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2581"},{"key":"2025100308264302000_13.1.e009415.16","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6820","article-title":"Efficacy and safety of radiotherapy combined with anti-angiogenic therapy and immune checkpoint inhibitors in MSS\/pMMR metastatic colorectal cancer","volume":"13","author":"Zhai","year":"2024","journal-title":"Cancer Med"},{"key":"2025100308264302000_13.1.e009415.17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","article-title":"Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database","volume":"8","author":"Anscher","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025100308264302000_13.1.e009415.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2025100308264302000_13.1.e009415.19","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02994-21","article-title":"Fecal Streptococcus Alteration Is Associated with Gastric Cancer Occurrence and Liver Metastasis","volume":"12","author":"Yu","year":"2021","journal-title":"MBio"},{"key":"2025100308264302000_13.1.e009415.20","doi-asserted-by":"publisher","DOI":"10.1021\/ac701982e"},{"key":"2025100308264302000_13.1.e009415.21","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"EClinMed"},{"key":"2025100308264302000_13.1.e009415.22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","article-title":"A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer","volume":"169","author":"Kim","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025100308264302000_13.1.e009415.23","doi-asserted-by":"crossref","first-page":"S1513","DOI":"10.1016\/j.annonc.2023.10.246","article-title":"111P Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study","volume":"34","author":"Wang","year":"2023","journal-title":"Ann Oncol"},{"key":"2025100308264302000_13.1.e009415.24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754881","article-title":"Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"2025100308264302000_13.1.e009415.25","first-page":"150","article-title":"Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial","volume":"41","author":"Yuan","year":"2023","journal-title":"J C O"},{"key":"2025100308264302000_13.1.e009415.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30380-7"},{"key":"2025100308264302000_13.1.e009415.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3427"},{"key":"2025100308264302000_13.1.e009415.28","doi-asserted-by":"crossref","unstructured":"Liu J , Liu C , Yue J . Radiotherapy and the gut microbiome: facts and fiction. Radiat Oncol 2021;16. doi:10.1186\/s13014-020-01735-9","DOI":"10.1186\/s13014-020-01735-9"},{"key":"2025100308264302000_13.1.e009415.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2015.01.004"},{"key":"2025100308264302000_13.1.e009415.30","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01273-9","article-title":"Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies","volume":"15","author":"Lu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025100308264302000_13.1.e009415.31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut Microbiota in Cancer Immune Response and Immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends Cancer"},{"key":"2025100308264302000_13.1.e009415.32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290"},{"key":"2025100308264302000_13.1.e009415.33","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1312","article-title":"The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer","volume":"13","author":"Han","year":"2023","journal-title":"Clin Transl Med"},{"key":"2025100308264302000_13.1.e009415.34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.21037\/tlcr.2019.10.23","article-title":"The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer","volume":"8","author":"Katayama","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2025100308264302000_13.1.e009415.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00203-017-1459-x"},{"key":"2025100308264302000_13.1.e009415.36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010038","article-title":"Gut Microbiota and Cancer: From Pathogenesis to Therapy","volume":"11","author":"Vivarelli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025100308264302000_13.1.e009415.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00661-4"},{"key":"2025100308264302000_13.1.e009415.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.11.013"},{"key":"2025100308264302000_13.1.e009415.39","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms5010010","article-title":"Lactobacillus gasseri PA-3 Uses the Purines IMP, Inosine and Hypoxanthine and Reduces their Absorption in Rats","volume":"5","author":"Yamada","year":"2017","journal-title":"Microorganisms"},{"key":"2025100308264302000_13.1.e009415.40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/15257770.2018.1454949","article-title":"Lactobacillus gasseri PA-3 utilizes the purines GMP and guanosine and decreases their absorption in rats","volume":"37","author":"Yamada","year":"2018","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2025100308264302000_13.1.e009415.41","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","article-title":"IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction","volume":"80","author":"Shiri","year":"2024","journal-title":"J Hepatol"},{"key":"2025100308264302000_13.1.e009415.42","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325808"},{"key":"2025100308264302000_13.1.e009415.43","unstructured":"Cheng MX , Jin M , Yang SL . Data from: Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observational study. Seq Read Archive (SRA) 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/sra\/?term=PRJNA1021317"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:26:52Z","timestamp":1759505212000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,4]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-009415"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009415","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}